Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | ACE | P12821 | 6/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.40 |
| ▸ | CASP3 | P42574 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17912899 | 0.87 | MAPT (0.51) | KMT2AALDH1A1 | |
| SCHEMBL17913006 | 0.82 | ROCK2 (0.51) | ACEBRD4 | |
| SCHEMBL17913005 | 0.81 | ACE (0.40) | KMT2AACEALDH1A1FKBP1A | |
| SCHEMBL19759533 | 0.80 | BRD4 (0.51) | KMT2AACEBRD4TDP1 | |
| SCHEMBL17920296 | 0.78 | KMT2A (0.44) | KMT2AACEALDH1A1BRD4TDP1 | |
| SCHEMBL17920300 | 0.77 | KMT2A (0.43) | KMT2AFKBP1A | |
| SCHEMBL17920287 | 0.77 | ROCK2 (0.47) | ACEALDH1A1TDP1 | |
| SCHEMBL31581789 | 0.76 | ALDH1A1 (0.54) | KMT2AALDH1A1TDP1 | |
| SCHEMBL17912896 | 0.76 | PKM (0.47) | KMT2A | |
| SCHEMBL11147455 | 0.73 | MEN1 (0.55) | KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107406426-B | Cyclic ureas as ROCK inhibitors | 百时美施贵宝公司 | 2020-11-20 | — | — | CN | disclosed |
| EP-3242873-B1 | CYCLIC UREAS AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2020-07-22 | — | — | EP | disclosed |
| EP-3242873-B1 | CYCLIC UREAS AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2020-07-22 | — | — | EP | disclosed |
| US-10123993-B2 | Cyclic ureas as inhibitors of rock | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-11-13 | — | — | US | disclosed |
| US-20180000788-A1 | CYCLIC UREAS AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2018-01-04 | — | — | US | disclosed |
| EP-3242873-A1 | CYCLIC UREAS AS INHIBITORS OF ROCK | Bristol-Myers Squibb Company (US) | 2017-11-15 | — | — | EP | disclosed |
| WO-2016112236-A1 | CYCLIC UREAS AS INHIBITORS OF ROCK | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-07-14 | — | — | WO | disclosed |
| WO-2016112236-A1 | CYCLIC UREAS AS INHIBITORS OF ROCK | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10123993-B2 | Cyclic ureas as inhibitors of rock | MYLK, ROCK1, UACA | KMT2A 2694/4885ACE 1320/4885ALDH1A1 2912/4885 |
| US-20180000788-A1 | CYCLIC UREAS AS INHIBITORS OF ROCK | MYLK, ROCK1, UACA | KMT2A 2694/4885ACE 1320/4885ALDH1A1 2912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.